Clariscan™

Stability refers to how tightly the gadolinium ion is bound to the chelating molecule and how likely it is to dissociate. Gadoteric acid is the only macrocyclic, ionic molecule across all gadoliunium-based contrast agents. In vitro data suggest that combining a macrocyclic structure for high kinetic stability, with ionicity for thermodynamic stability, may help to reduce the potential risk of gadolinium dissociation.¹

Clariscan is indicated for diagnostic contrast enhancement in³:

• MRI of the CNS including the brain, spine and surrounding tissue
• Whole body MRI including the major organs, pelvis, breast and muscoskeletal system (not recommended for children below 6 months)
• MR angiography including lesions or stenoses of the non-coronary arteries (adults only)

Clariscan should be used when diagnostic information is essential and not available with unenhanced magnetic resonance imaging (MRI).

Clariscan has been approved in more than 80 countries with over 17 million doses shipped globally. There are no signals to suggest that the safety profile of Clariscan is different to that established for the reference product, Dotarem®.²

Clariscan offers a range of packaging:

• Glass vials: 5, 10, 15, and 20 mL
• Clear plastic prefilled syringes: 10, 15, and 20 mL
• +PLUSPAK polymer bottles: 50 and 100 mL

Our unique +PLUSPAK packaging reduces hazard and downtime:

• No more broken bottles, glass or ring-pull injuries⁴

It also reduces costs and environmental impact:

• Less storage space, lower disposal costs, reduced environmental impact⁴⁻⁶

GE HealthCare has invested over $385M since 2013 in expansion of our manufacturing capacity to meet growing demand for our contrast agents. All our manufacturing sites are cGMP-accredited and we work closely with regulatory agencies globally to ensure quality supply.⁷